Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients
NCT07631650
Head and Neck Cancer, Head and Neck Disorder
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT Number: NCT07690631
MICRORAD is a pioneering 48-month translational research project that investigates the potential health and environmental impacts of micro- and nanoplastics (MNPs) released from medical devices when exposed to ionizing radiation. In radiation oncology, thermoplastic masks (TPMs) are standard immobilization tools, particularly for head and neck (HN) cancer patients. Globally, approximately 2.65 million TPMs are used annually in the radiotherapy of HN cancer patients and with an additional 8 to 10 million for other tumor types. TPMs are repeatedly subjected to high-energy X-rays and frequent handling, raising concerns about polymer degradation and the release of MNPs, which may interfere with treatment efficacy or contribute to radiation toxicity.
MICRORAD is the first translational study to explore this phenomenon by integrating clinical oncology, materials science, radiobiology, and data science. The project will analyze radiation-induced changes in TPMs, quantify MNP release, and assess their biological effects through in vitro, in vivo, and clinical studies.
Using advanced detection techniques, the project will characterize MNPs and trace their biodistribution, while a clinical pilot will correlate MNP exposure with treatment outcomes. Data integration, biostatistics, and AI-based modeling will support the translation of findings into clinical guidelines, policy briefs, and public communication.
A multidisciplinary team will collaborate to ensure real-world impact. By bridging oncology and environmental health, MICRORAD aims to establish eco-oncology as a new field, contributing to patient safety and sustainable innovation.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From enrollment to the 6 month FU treatment
To characterize MNPs and trace their biodistribution and to correlate MNP exposure with treatment outcomes
Contact information is provided by the study sponsor or research team.
Marija N Zivkovic Radojevic, Assistant Professor, MD PhD
CONTACT
Neda Milosavljevic, Assistant Professor, MD PhD
CONTACT
University of Kragujevac
Other
Acronym: MICRORAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07631650
Head and Neck Cancer, Head and Neck Disorder
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07667400
Adenocarcinoma, Adenoid Cystic Carcinoma
Bethesda, Maryland, United States
View Trial DetailsNCT04662554
Head and Neck Cancer, Head and Neck Neoplasms
Stanford, California, United States
View Trial DetailsNCT07630168
Bronchial Neoplasms, Carcinoma
Chapel Hill, North Carolina, United States
View Trial Details